"We may now have multiple, very effective vaccines distributing widely in spring and summer", he added.
"Most Covid-19 vaccines need extremely cold temperature for storage and transportation", DAK President and influenza expert Dr Nisar ul Hassan said.
Moderna's vaccine is among 11 candidates in late-stage testing around the world, four of them in huge studies in the U.S. Moderna's shares rocketed higher on its announcement Monday and appeared to be headed for an all-time high Monday.
CEO Stéphane Bancel said the company previously thought the shots could only be refrigerated for seven days.
Moderna expects to have enough safety data required for US authorization in the next week or so and expects to file for emergency use authorization (EUA) in the coming weeks.
Furthermore, data from the two trials do not indicate how long the protection afforded by the vaccines lasts.More news: SpaceX, NASA launch 4 astronauts from Kennedy Space Center
The analysis by an independent monitoring board does not mean an effectivevaccine is imminent, but the early results are impressive. The company plans to release additional results later, including effectiveness in specific groups such as the elderly and against infections that don't produce symptoms.
Russian Federation licensed its Sputnik-V Covid-19 vaccine for domestic use in August before it released data from large-scale trials. This time by Moderna, 95% effective.
The estimate of the efficacy is based on the number of Covid-19 cases that have been reported during the trial.
One of the concerns about the messenger RNA vaccine developed by Pfizer and its German partner BioNTech is that it must be kept at minus-94 degrees Fahrenheit or lower.
Covid-19 vaccines developed in China and Russian Federation have already been administered, though they haven't finished the final stage of testing. It said on November 11 that its vaccine was 92% effective based on 20 infections in its large trial. It works by injecting in the human body a small fragment of the virus's genetic code.
Interim data from the U.S. firm Moderna suggests its vaccine is highly effective in preventing people getting ill and works across all age groups.
The study's design called for the independent committee to conduct the first interim analysis of efficacy when 53 people came down with symptomatic Covid-19.More news: Trump Once Again Insists He'll Win Election After MAGA Rallies
The 95 cases of COVID-19 included several key groups who are at increased risk for severe disease, including 15 cases in adults aged 65 and older and 20 in participants from racially diverse groups. "This is a really strong step forward to where we want to be".
The two companies are reportedly ready to distribute a combined 60 million doses of COVID-19 vaccines throughout the United States before 2021.
The promising results of both vaccines are seen as a validation for mRNA technology, which has never before been brought to regulatory approval.
Now, officials say that between the two companies there will be enough doses to vaccinate 20million Americans by the end of this year.
Plans haven't been finalized, but a National Academy of Medicine committee has recommended that the first phase of vaccination cover about 5% of the population and include front-line health workers such as those in hospitals and nursing homes, workers who provide transportation and other services to health-care facilities, and first responders.
Moderna is working with contract manufacturers to boost production so it can make 500 million to one billion doses next year. US officials said they hope to have about 20 million Moderna doses and another 20 million doses of the vaccine made by Pfizer and its German partner BioNTech to use in late December. Moderna also said it would use its data to seek authorization in Europe and other regions. "Till the vaccine becomes available, people should continue with the best tools that we already have - social distancing, wearing masks and washing your hands", he added.More news: South Australia hit by growing cluster of Covid-19 cases